Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (7)	7/12/2006 12:33:01 PM
From: keokalani'nui	Respond to of 285

>>I feel their RTF letter might be just due to the recent FDA's electronic version formatting problems.<< Not quite. True, the conclusion/presentation data was not properly footnoted to the detailed data sections. That is, the way the data was linked to the assertions was inadequate. But further, the fda apparently ran a quick audit on one of the charts and it didn't foot. At that point the fda had spent probably 30 minutes with it and said we don't trust anything in here. Also, Astellas chose to file a "Common Technical Document" instead of the more common NDA. This likely also added to the fda's discomfort level.